A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Phase 4
- Conditions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT00354445
- Locations
- ๐บ๐ธ
Retina Research Institute of Texas, LLC, Abilene, Texas, United States
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2006-05-04
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00321997
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Phase 4
Terminated
- Conditions
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 262
- Registration Number
- NCT00312351
- Locations
- ๐บ๐ธ
Charlotte Eye, Ear, Nose and Throat Associates, P.A., Charlotte, North Carolina, United States
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT00215670
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT00134667
- Locations
- ๐บ๐ธ
Retina Centers, P.C., Northwest Location, Tucson, Arizona, United States
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2007-01-19
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT00088283
- Locations
- ๐บ๐ธ
Jules Stein Institute, Los Angeles, California, United States
๐บ๐ธOrange County Retina Associates, Santa Ana, California, United States
๐บ๐ธCumberland Valley Retina Center, Hagerstown, Maryland, United States
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Not Applicable
Completed
- Conditions
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2005-08-30
- Lead Sponsor
- Eyetech Pharmaceuticals
- Registration Number
- NCT00088192
- Locations
- ๐บ๐ธ
Eye Foundation of Kansas City, Kansas City, Missouri, United States
๐บ๐ธThe Eye Center of Concord, Concord, New Hampshire, United States
๐บ๐ธRetina Associates of Cleveland Inc., Lakewood, Ohio, United States
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT00087763
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Registration Number
- NCT00040313
Phase II/III Study of Anti-VEGF in Neovascular AMD
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00021736
- Locations
- ๐บ๐ธ
Foundation for Fighting Blindness, Baltimore, Maryland, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath